



10TH ANNUAL REPORT

2019-20

**NOVA HEALTH SCIENCES PRIVATE
LIMITED**



Corporate Information

Board of Directors:

Sambasivarao Yeluri
Malathi Siripurapu

Director
Director

Corporate Identity Number: U8S190TG2010PTC068S84

Registered Office

S.Y.No: 2,S L/A/1, Singannaguda Village, Mulugu Mandal, Siddipet District -S02279, Telengana

E-Mail: novahealthsciences789@gmail.com

Statutory Auditors:

M/s. NSVR and Associates LLP,
Chartered Accountants,
FRN: 008801S/S200060
Address: Plot No. 28, Flat No. 101,
Nestcon Gayatri, Road No. 10,
Banjara Hills, Hyderabad-S00034, Telangana.

NOVA HEALTH SCIENCES PRIVATE LIMITED

CIN: U85190TG2010PTC068584

R.O.: S.Y.No:2,5L/1,SINGANNAGUDA VILLAGE, MULUGU MANDAL, SIDDIPET DISTRICT -502279

NOTICE

Notice is hereby given that the 10th Annual General Meeting of the members of '**Nova Health Sciences Private Limited**' ("**The Company**") will be held on Thursday, the 31st day of December 2020, at 11.30 A.M. at its registered office situated at S.Y.No; 2,5L/A/1,Singannaguda Village, Mulugu Mandal, Siddipet District 502279 2-1-107/04, Telangana, for transacting the following business:

ORDINARY BUSINESS:

1. Adoption of Audited Financial Statements of the Company for the financial year ended 31st March, 2020 and the reports of the Auditors and Board of Directors thereon.


To consider and if thought fit, to pass with or without modification(s) the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of section 129 and all other applicable provisions of the Companies Act, 2013 and Rules made there under the Audited Financial Statements of the Company for the financial year ended 31st March, 2020, together with the Report of the Board of Directors and the Auditors thereon, be and are hereby considered, approved and adopted."

"RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do or cause to be done all such acts, deeds and things as may be required or considered necessary or incidental thereto for giving effect to the aforesaid resolution."

Order of the Board
For Nova Health Sciences Private Limited

Date: 28.09.2020
Place: Singannaguda



Sambasivarao Yeluri
Director
DIN: 02311336

NOVA HEALTH SCIENCES PRIVATE LIMITED

CIN: U55190TG2010PTC068584

R.O.: S.Y.No: 2,5 L/A/1, Singannaguda Village, Mulugu Mandal, Siddipet District-502279 Telangana.

DIRECTORS' REPORT

Your Directors have pleasure in presenting the 10th (TENTH) ANNUAL REPORT on the business and operations of the Company together with the Audited Financial Statements for the Financial Year ended March 31, 2020.

FINANCIAL PERFORMANCE:

(Values in Rs.)

Particulars	Year Ended March 31, 2020	Year Ended March 31, 2019
Income from Operations	158100	0
Other income	0	0
Total income	158100	0
Total Expenditure	153390	7000
Profit Before Tax	4710	(7000)
Less: Tax expenses	0	0
Net Profit/Loss	4710	(7000)

SUMMARY OF OPERATIONS & STATE OF COMPANY'S AFFAIRS:

During the financial year under review your company recorded a profit for the FY 2019-20 Rs.- 4710 as against a loss of Rs. 7000/- for the FY 2018-19. The affairs of the Company are conducted in accordance with the accepted business practices and within the purview of the applicable legislations.

SUBSIDIARY COMPANIES/JOINT VENTURES/ASSOCIATE COMPANIES:

The Company does not have any Subsidiary Company, Joint Ventures. During the year under review no Company has become/ceased to be its Subsidiary, Joint Venture or Associate of Company.

SHARE CAPITAL:

The paid- up Equity Share Capital as at March 31, 2020 stood at Rs. 1,00,000/-. During the year, under review, there is no change in the capital structure of the company.

CHANGE IN THE NATURE OF BUSINESS

There is no change in the nature of the business during the financial year under review.

DIVIDEND:

The Board of directors do not recommend any Dividend for the year under review.

TRANSFERS TO RESERVES:

During the year under review, the company has transferred profit of Rs.4710/- to reserves for the financial year 2019-20.

MATTERS RELATED TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:

During the year under review, there was no change in the composition of the Board of Directors.

Key Managerial Personnel:

During the year under review, the company is not mandated to appoint any Key Managerial Person.

NO. OF BOARD MEETINGS HELD DURING THE YEAR:

The Board of Directors duly met 6 (Six) times and in respect of which meetings, proper notices were given and the proceedings were properly recorded.

DIRECTORS' RESPONSIBILITY STATEMENT:

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the Internal, Statutory Auditors and the reviews performed by Management and the Board, the Board is of the opinion that the Company's internal financial controls were adequate and effective during the financial year 2019-20.

Accordingly, pursuant to Section 134 (3) (c) and 134 (5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- i. in the preparation of the annual accounts for the year ended March 31, 2020, the applicable accounting standards have been followed and there are no material departures;
- ii. accounting policies have been selected and applied consistently and judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company as at FY ended March 31, 2020 and of the profit and loss of the Company for that period on that date;
- iii. proper and sufficient care have been taken for the maintenance of accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company, for preventing & detecting fraud and/or other irregularities;

- iv. the annual accounts have been prepared on a going concern basis;
- v. internal financial controls have been laid down by the Company and that such internal financial controls are adequate and are operating effectively; and
- vi. proper systems have been devised to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

STATUTORY AUDITORS:

Pursuant to Section 139, 141 & 142, and other applicable provisions, if any, of the Companies Act, 2013, M/s. NSVR & ASSOCIATES LLP, Chartered Accountants (Firm Registration No. 008801S/S200060) were re-appointed by the Shareholders of the Company as Statutory Auditors of the Company to hold office from the conclusion of the 9th Annual General Meeting of the Company to the conclusion of the 14th Annual General Meeting to conduct the Statutory Audit of the Company for the financial years commencing from 2019-20 to 2023-24.

REPLIES TO THE STATUTORY AUDITOR'S REMARKS

The Auditors Report for the financial year ended 31st March, 2020 does not contain any qualification, adverse remark or reservation and therefore, do not call for any further explanation or comments from the Board under Section 134 (3) of the Companies Act, 2013.

FRAUDS REPORTED BY THE AUDITORS

There are no frauds reported by auditors under sub-section (12) of section 143.

COST RECORDS/ COST AUDIT

As per the criteria laid down in Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014 as amended from time to time, your Company is not required to maintain of cost records and accordingly cost audit is not applicable to your company.

PUBLIC DEPOSITS

During the Financial Year 2019-20, your Company has not accepted/ not required to renew any deposit that falls within the meaning of Section 73 and 74 of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES, INVESTMENTS UNDER SECTION 186:

During the year under review, the Company has not given any loan/ provided guarantee/ made any investments as specified under the provisions of section 186 of the Companies Act, 2013.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments, affecting the financial position of the Company which have occurred during/ after the balance sheet date till the date of this directors' report.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNALS

During the Financial year under review, no significant and material orders passed by regulators or courts or tribunals impacting the going concern status and company operations in future.

RISK MANAGEMENT FRAMEWORK:

The Company has a robust internal business management framework to identify, evaluate business risks and opportunities which seeks to minimize adverse impact on the business objectives and enhance the Company's business prospects.

EXTRACT OF ANNUAL RETURN:

The details forming part of the extract of the Annual Return in form MGT 9 as required under Section 92 of the Companies Act, 2013, is annexed herewith as 'Annexure I' to this report.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

During the year under review, there were no contracts or arrangements entered with related parties. For the details of related party transactions for the FY 2019-20, please refer notes to audited financial statements.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

Conservation of energy:

The operations of the Company are not energy-intensive. However, The Company is making continuous efforts on ongoing basis to conserve the energy by adopting innovative measures to reduce wastage and optimize consumption.

	The steps taken or impact on conservation of energy	The operations of the company are not energy intensive, adequate measures have, however, been taken, to conserve and reduce wastage and optimize consumption.
	The steps taken by the company for utilizing alternate sources of energy	
	The Capital investment on energy conservation equipment's	

Technology Absorption: Nil

Foreign Exchange Earnings & Outgo: Nil

(Amount in Rs.)

Particulars	2019-20	2018-19
Foreign Exchange earnings	0	0
Foreign Exchange outgo	0	0

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to Section 135 and Schedule VII of the Companies Act, 2013, the company do not fall under the class of companies as provided in the Act, hence, provisions of CSR shall not apply to the company.

PARTICULARS OF EMPLOYEES

There is no Employee drawing remuneration aggregating to the limits prescribed under the provisions of Section 134(3)(q) of the Companies Act, 2013 read with Rule 5(2) the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The management has established and maintaining adequate internal financial controls to ensure orderly and efficient conduct of its business including adherence to company's policies to safeguard its assets, prevent and detect frauds and errors, check the accuracy and completeness of accounting records and prepare financial information.

RISK MANAGEMENT POLICY

The Company has developed and implemented a risk management policy which identifies major risks which may threaten the existence of the Company. The same has also been adopted by your Board and is also subject to its review from time to time. Risk mitigation process and measures have been also formulated and clearly spelled out in the said policy.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The following is a summary of sexual harassment complaints received and disposed off during each Calendar year:


- No. of complaints received : Nil
- No. of complaints disposed off : Nil

APPRECIATION:

The Directors express their appreciation to all employees of the various divisions for their diligence and contribution to performance. The Directors also record their appreciation for the support and co-operation received from bankers and all other stakeholders. Last but not the least, the Directors wish to thank all shareholders for their continued support.

By Order of the Board
For Nova Health Sciences Private Limited

Date: 28.09.2020
Place: Singannaguda



Sambasivarao Yeluri
Director
DIN: 02311336



Malathi Siripurapu
Director
DIN: 03033944

NOVA HEALTH SCIENCES PRIVATE LIMITED

Annexure-I

Form No. MGT-9

EXTRACT OF ANNUAL RETURN

For the financial year ended 31st March 2020

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i.	CIN	U85190TG2010PTC068584
ii.	Registration Date	25/05/2010
iii.	Name of the Company	Nova Health Sciences Private Limited
iv.	Category / Sub-Category of the Company	Private Limited Company
v.	Address of the Registered office and contact details	S.Y.No:2,5 L/A/1 Singannaguda Village Mulugu Mandal, Siddipet District- 502279
vi.	Whether listed Company	No
vii.	Name, Address & Contact details of Registrar & Transfer Agent, if any	NA

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

S. No.	Name and Description of main products / service	NIC Code of the Product/ Service	% to total turnover of the Company
1	Medicinal chemical	2100	100

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S. No.	Name of The Company	CIN	Holding/ Subsidiary/ Associate/ Joint Venture	% of shares held

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

(i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year (01-04-2019)				No. of Shares held at the end of the year (31-03-2020)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/HUF	0	10,000	10,000	100	0	10,000	10,000	100	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	0	0	0	0	0	0	0	0
e) Banks / FI	0	0	0	0	0	0	0	0	0
f) Any Other.... (Directors Relatives)	0	0	0	0	0	0	0	0	0
Sub-total (A) (1):-	0	10,000	10,000	100	0	10,000	10,000	100	0
(2) Foreign									
g) NRIs - Individuals	0	0	0	0	0	0	0	0	0
h) Other – Individuals	0	0	0	0	0	0	0	0	0
i) Bodies Corp.	0	0	0	0	0	0	0	0	0
j) Banks / FI	0	0	0	0	0	0	0	0	0
k) Any Other....	0	0	0	0	0	0	0	0	0
Sub-total (A) (2):-	0	10,000	10,000	10,000	0	10,000	10,000	100	0
Total shareholding of Promoter (A) = A(1)+A(2)	0	0	0	0	0	0	0	0	0
B. Public Shareholding									
(1) Institutions									
a) Mutual Funds	0	0	0	0	0	0	0	0	0
b) Banks / FI	0	0	0	0	0	0	0	0	0
c) Central Govt	0	0	0	0	0	0	0	0	0
d) State Govt(s)	0	0	0	0	0	0	0	0	0
e) Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance Companies	0	0	0	0	0	0	0	0	0
g) FIs	0	0	0	0	0	0	0	0	0
h) Foreign Venture Capital Funds									
i) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(1):-	0	0	0	0	0	0	0	0	0

(2) Non-

Institutions									
a) Bodies Corp.									
i) Indian	0	0	0	0	0	0	0	0	0
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals									
i) Individual Shareholders holding nominal share capital upto Rs. 1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
i) NRI's	0	0	0	0	0	0	0	0	0
ii) Market Makers	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs&ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	10,000	10,000	100	0	10,000	10,000	100	0

(ii) Shareholding of Promoters:

S. No.	Shareholder's Name	Shareholding at the beginning of the year (01-04-2019)			Shareholding at the end of the year (31-03-2020)			% change in Share holding during the year
		No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1.	Yeluri Sambasiva Rao	8,000	80%	Nil	8,000	80%	Nil	Nil
2.	Malathi Siripurapu	2,000	20%	Nil	2,000	20%	Nil	Nil
	Total	10,000	100.00	0	10,000	100.00	0	0

(iii) Change in Promoters' Shareholding (please specify, if there is no change):

S. No.		Shareholding at the beginning of the year			Cumulative Shareholding during the year		
		No. of Shares	% of total shares of the Company	Cumulative share holding	No. of Shares	% of total shares of the Company	Cumulative shareholding
I.	At the beginning of the year	10,000					
	Date wise Increase / Decrease in Promoters Share Holding during the Year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/sweat equity etc):	No Changes during the year					
3.	At the end of the year	10,000					

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Not Applicable

(v) Shareholding of Directors and Key Managerial Personnel:

S. No.	Name	Shareholding					Cumulative Shareholding during the year	
		No. of Share at the Beginning (01.04.2019) / end of the year (31.03.2020)	% of total Shares of the Company	Date	Increase / Decrease in Shareholding	Reason	No. of shares	% of Total Shares of the Company
1.	Yeluri Sambasiva Rao	8,000	80.00%	01-04-2019			8,000	80.00%
		8,000	80.00%	31-03-2020	-	-		
2.	Malathi Siripurapu	2,000	20.00%	01-04-2019	-	-	2,000	20.00%
		2,000	20.00%	31-03-2020	-	-		

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due:

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	0	25,500	0	25,500
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0
Change in Indebtedness during the financial year				
* Addition	0	0	0	0
* Reduction	0	0	0	0
Net Change	0	0	0	0
Indebtedness at the end of the financial year				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL: NIL

(i) Remuneration to Managing Director, Whole-time Directors and/or Manager: *Not Applicable*

S. No.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount
1.	Gross salary (a)Salary as per provisions containedinsection17(1) of the Income-tax Act, 1961 (b)Value of perquisites u/s 17(2)Income-tax Act, 1961 (c)Profits in lieu of salary undersection17(3)Income-taxAct,1961	NA	NA
2.	Stock Option	NA	NA
3.	Sweat Equity	NA	NA
4.	Commission - as % of profit - others, specify...	NA	NA
5.	Others ,please specify	NA	NA
Total(A)		NA	NA

(ii) Remuneration to other directors:


S. No.	Particulars of Remuneration	Amount
1.	Gross salary (a)Salary as per provisions containedinsection17(1) of the Income-tax Act, 1961 (b)Value of perquisites u/s 17(2)Income-tax Act, 1961 (c)Profits in lieu of salary undersection17(3)Income-taxAct,1961	NA
2.	Stock Option	NA
3.	Sweat Equity	NA
4.	Commission - as % of profit - others, specify...	NA
5.	Others ,please specify	NA
Total(A)		NA

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

There were no penalties / punishment / compounding of offences for the year ending March 31, 2020.

By Order of the Board
For Nova Health Sciences Private Limited

Date: 28.09.2020
Place: Singannaguda



Sambasivarao Yeluri
Director
DIN: 02311336



Malathi Siripurapu
Director
DIN: 03033944

INDIAN INCOME TAX RETURN ACKNOWLEDGEMENT

[Where the data of the Return of Income in Form ITR-1 (SAHAJ), ITR-2, ITR-3,
ITR-4(SUGAM), ITR-5, ITR-6, ITR-7 filed and verified]
(Please see Rule 12 of the Income-tax Rules, 1962)

Assessment Year
2020-21

PAN	AAGCN0627B		
Name	NOVA HEALTH SCIENCES PRIVATE LIMITED		
Address	2-1-107/04 BEHIND NO8LE, ENCLAVE KOMPALLY, QUTHBULLAPUR, 8EHIND NOBLE ENCLAVE, SECUNDERABAD, TELANGANA, 500014		
Status	Pvt Company	Form Number	ITR-6
Filed u/s	139(1)-On or before due date	e-Filing Acknowledgement Number	23S781821010221

Taxable Income and Tax details			
	Current Year business loss, if any	1	0
	Total Income		0
	Book Profit under MAT, where applicable	2	0
	Adjusted Total Income under AMT, where applicable	3	0
	Net tax payable	4	0
	Interest and Fee Payable	5	0
	Total tax, interest and Fee payable	6	0
	Taxes Paid	7	0
	(+)Tax Payable /(-)Refundable (6-7)	8	0
Dividend Distribution Tax details			
	Dividend Tax Payable	9	0
	Interest Payable	10	0
	Total Dividend tax and interest payable	11	0
	Taxes Paid	12	0
	(+)Tax Payable /(-)Refundable (11-12)	13	0
Accreted Income & Tax Detail			
	Accreted Income as per section 115TD	14	0
	Additional Tax payable u/s 115TD	15	0
	Interest payable u/s 115TE	16	0
	Additional Tax and interest payable	17	0
	Tax and interest paid	18	0
	(+)Tax Payable /(-)Refundable (17-18)	19	0

Income Tax Return submitted electronically on 01-02-2021 16:22:51 from IP address 183.82.110.4 and verified by SAMBASIVA RAO YELURI

having PAN ABWPY6361M on 01-02-2021 16:22:51 from IP address 183.82.110.4 using

Digital Signature Certificate (DSC).

DSC details: 18598255CN=e-Mudhra Sub CA for Class 2 Individual 2014,OU=Certifying Authority,O=eMudhra Consumer Services Limited,C=IN

DO NOT SEND THIS ACKNOWLEDGEMENT TO CPC, BENGALURU

1 Y. Sambasiva Rao 2 S. Malathi



NOVA HEALTH SCIENCES PRIVATE LIMITED
2-1-107/04, BEHIND NOSLE ENCLAVE KOMPALLY QUTHBULLAPUR SECUNDERABAD HYDERABAD 500014
BALANCE SHEET AS ON 31st MARCH, 2020

PARTICULARS	Notes	As At 31.03.2020	As At 31.03.2019
I. EQUITY AND LIABILITIES :			
1. Shareholders Funda :			
(a) Share Capital	1	1,00,000	1,00,000
(b) Reserves And Surplus	2	(30,414)	(35,124)
(c) Money Received Against Share Warrants		-	-
2. Share Application Money Pending Allotment :			
3. Non Current Liabilities :			
(a) Long-Term Borrowings	3	25,500	25,000
(b) Deferred Tax Liability		-	-
4. Current Liabilities :			
(a) Short-Term Borrowings			
(b) Trade Payables	4	3,96,995	
(c) Short-Term Provisions		-	-
(d) Other Current Liabilities	5	49,682	7,000
TOTAL		5,41,763	96,876
II. ASSETS :			
1. Non-Current Assets :			
(a) Fixed Assets			
i) Tangible Assets		-	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)		-	-
(d) Long-term loans and advances		-	-
(e) Other Non Current Assets		-	-
2. Current Assets :			
(a) Inventories	6	2,65,838	-
(b) Trade Receivables	7	1,66,007	-
(c) Cash And Cash Equivalents	8	17,576	17,196
(d) Short-Term Loans And Advances	9	79,680	79,680
(e) Other Current Assets	10	12,662	-
TOTAL		5,41,763	96,876

SIGNIFICANT ACCOUNTING POLICIES & NOTES

In terms of our report attached.

For NSVR & ASSOCIATES LLP

Chartered Accountant

FRN: 008801S/S200060



VENKATARTNAM P

Partner


Membership No. 230675

UDIN : 21230675AAAADJ2620

Place: Hyderabad

Date: 28-09-2020

For and on behalf of the Board of Directors
NOVA HEALTH SCIENCES PRIVATE LIMITED



SAMBASIVARAO YELURI

DIRECTOR

DIN No. 02311336



MALATHI SIRIPURAPU

DIRECTOR

DIN No. 03033944

NOVA HEALTH SCIENCES PRIVATE LIMITED

2-I-107/04, BEHIND NOBLE ENCLAVE KOMPALLY QUTHBULLAPUR SECUNDERABAD HYDERABAD S00014

STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31-03-2020

Particulars	Notes	2019-2020	2018-2019
I. Revenue from operations	11	1,58,100	-
II. Other income		-	-
III. Total Revenue (I + II)		1,58,100	-
IV. Expenses:			
Purchases	12	3,76,428	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	13	(2,65,838)	-
Employee benefits expense	14	-	-
Finance costs		-	-
Operating Expenses		-	-
Depreciation and amortization expense		-	-
Other expenses	15	42,800	7,000
Total expenses		1,53,390	7,000
Profit before exceptional and extraordinary items and tax (III-IV)		4,710	(7,000)
VI. Exceptional items (Prior Period Item)		-	-
VII. Profit before extraordinary items and tax (V - VI)		4,710	(7,000)
VIII. Extraordinary Items		-	-
IX. Profit before tax (VII- VIII)		4,710	(7,000)
X Tax expense:			
(1) Current tax		-	-
(2) Deferred tax Liability		-	-
Profit (Loss) for the period from continuing operations (VII-VIII)		4,710	(7,000)
XII Profit/(loss) from discontinuing operations		-	-
XIII Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		4,710	(7,000)
XV Profit (Loss) for the period (XI + XIV)		4,710	(7,000)
XVI Earnings per equity share:			
(1) Basic		0.47	(0.70)
(2) Diluted		0.47	(0.70)
SIGNIFICANT ACCOUNTING POLICIES & NOTES	A		

For NSVR & ASSOCIATES LLP

Chartered Accountant

FRN: 008801S/S200060

VENKATARATNAM P

Partner

Membership No. 230675

UDIN : 21230675AAAADJ2620

Place: Hyderabad

Date: 28-09-2020

For and on behalf of the Board of Directors of
NOVA HEALTH SCIENCES PRIVATE LIMITED


SAMBASIVARAO YELURI

Director

DIN: 02311336



MALATHI SIRIPURAPU

Director

DIN: 03033944

NOVA HEALTH SCIENCES PRIVATE LIMITED
NOTES FORMING PART OF THE BALANCE SHEET

NOTE 1 : SHARE CAPITAL

A) Details of the Authorized, Issued, Subscribed and Paid up share capital have been depicted in the table below :

Particulars	31 March, 2020		31 March, 2019	
	Number of shares	Amount	Number of shares	Amount
(a) Authorised 10,000 Equity shares of Rs.10/- each with voting rights	10,000	1,00,000	10,000	1,00,000
(b) Issued, Subscribed and Paid up 10,000 Equity shares of Rs.10/- each with voting rights	10,000	1,00,000	10,000	1,00,000
Total	10,000	1,00,000	10,000	1,00,000

B) Reconciliation of shares outstanding at the beginning and at the end of the reporting period

Particulars	31 March, 2020		31 March, 2019	
	Number of shares	Amount	Number of shares	Amount
No. of Equity shares outstanding at the beginning of the year	10,000	1,00,000	10,000	1,00,000
Add : Shares allotted during the year	-	-	-	-
Less: Shares bought back during the period	-	-	-	-
No. of Equity shares outstanding at the End of the year	10,000	1,00,000	10,000	1,00,000

C) List of Shareholders holding more than 5% share capital

Name of Shareholders	31 March, 2020		31 March, 2019	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
a) Yeluri Sambasiva Rao	8,000	80	8,000	80
b) Y. Malathi	2,000	20	2,000	20
TOTAL	10,000	100	10,000	100

Terms and rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10/- per share. Each holder of equity shares is entitled to one vote per share. No dividend was proposed by the Board of Directors during the year.



P. Sambasiva Rao
- S. Malathi

NOTE - 2 : RESERVES & SURPLUS

Particulars	31-03-2020	31-03-2019
Surplus :		
Opening Balance	(35,124)	(28,124)
Add : Net Profit / (Loss)	4,710	(7,000)
TOTAL	(30,414)	(35,124)

NOTE - 3 : LONG TERM BORROWINGS

Particulars	31-03-2020	31-03-2019
Loans from related parties	25,500	25,000
Total	25,500	25,000

NOTE - 4 : TRADE PAYABLE

Particulars	31-03-2020	31-03-2019
SUNDRY CREDITORS	3,96,995	
Total	3,96,995	-

NOTE - 5 OTHER CURRENT LIABILITIES

Particulars	31-03-2020	31-03-2019
Audit Fee Payable	49,682	7,000
Total	49,682	7,000

Y. Sambhu

S. Malathi



NOTE -6 INVENTORIES

Particulars	AS AT 31-03-2020	AS AT 31-03-2019
Stock	2,65,838	-
Total	2,65,838	-

NOTE 7 -TRADE RECEVIBLES

Particulars	AS AT 31-03-2020	AS AT 31-03-2019
SUNDRY DEBTORS	1,66,007	
Total	1,66,007	-

NOTE 8 - CASH AND CASH EQUIVALENTS

Particulars	AS AT 31-03-2020	AS AT 31-03-2019
Cash on hand	17,196	17,196
bank	380	
Total	17,576	17,196

NOTE -9 SHORT TERM LOANS AND ADVANCES

Particulars	AS AT 31-03-2020	AS AT 31-03-2019
Other loans and advances	79,680	79,680
Total	79,680	79,680

NOTE -10 OTHER CURRENT ASSETS

Particulars	AS AT 31-03-2020	AS AT 31-03-2019
Balance with Revenue Authorities	12,662	-
Total	12,662	-



P. Srinivas

S. Malathi

NOVA HEALTH SCIENCES PRIVATE LIMITED
NOTES FORMING PART OF STATEMENT OF PROFIT AND LOSS

NOTE - 11 : REVENUE FROM OPERATIONS

Particulars	F.Y 2019-20	F.Y 2018-19
Sale of Services	1,58,100.00	-
Total	1,58,100.00	-

NOTE - 12 PURCHASES

Particulars	F.Y 2019-20	F.Y 2018-19
Purchases	3,76,428.00	-
Total	3,76,428.00	-

NOTE - 13 : CHANGE IN INVENTORIES

Particulars	F.Y 2019-20	F.Y 2018-19
Opening Stock of Inventory	-	-
Closing Stock of Inventory	2,65,837.76	-
Total	2,65,837.76	-

NOTE - 14 : EMPLOYEE BENEFIT EXPENSES

Particulars	F.Y 2019-20	F.Y 2018-19
Salaries		-
Total	-	-

NOTE - 15 : OTHER EXPENSES

Particulars	F.Y 2019-20	F.Y 2018-19
Office Expenses	-	-
Audit Fees	7,000	7,000
bank charges	118	
Total	7,118	7,000



Y. Senthilraj *S. Malathi*

NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2019-20
NOTES forming part of the Financial Statements

Note A Significant Accounting Policies

1. Corporate Information:

NOVA HEALTH SCIENCES PRIVATE LIMITED is registered as a Private Limited Company under the Companies Act 1956 in the state of Telangana. The Corporate Identification number of the company is U85190TG2010PTC068584 was registered on 25th May, 2010.

2. Basis of preparation of financial Statements:

The Financial statements have been prepared in accordance with the generally accepted accounting principles and in India (Indian GAAP) to comply with the Accounting standards specified in section 133 of the companies Act, 2013 and the relevant provisions of the Act as applicable. The Financial Statements of the company are prepared under historical cost convention using the accrual method of accounting.

All assets and liabilities have been classified as current or non-current as per the operating cycle criteria set out in the Revised Schedule III to the Companies Act, 2013.

3. The Company's Summarized Significant accounting policies are stated below -

A. Use of Estimates:

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/ materialized.

B. Fixed Assets:

Fixed assets are recognized at cost of acquisition and installation less accumulated depreciation. The cost comprises purchase price, freight, duties, levies, borrowing cost and directly attributable cost of bringing the assets to their working condition for intended use as per the accounting Standard 10 "accounting for fixed assets". Subsequent expenditure related to an item of fixed assets is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance or extend its estimated useful life.



Y. Sambhally

S. Malathi

NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2019-20
NOTES forming part of the Financial Statements

C. Revenue Recognition:

Revenue is recognized on the basis of invoice raised or receipt of revenue whichever is earlier.

D. Taxation:

i) Current Tax:

Current tax expenses are accounted in the same period to which the revenue and expenses relate. Provision for current income tax is made for the tax liability payable on taxable income after considering tax allowances, deductions and exemptions determined in accordance with the applicable tax rates and the prevailing tax laws.

ii) Deferred Tax:


Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period and which are capable of reversal in one or more subsequent period(s) is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is virtual certainty with respect to the reversal of the same in future years. Deferred tax assets are reviewed at each balance sheet date and are written-down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realized.

E. Earnings per share:

Basic Earnings per Share is calculated by dividing the net earnings after tax for the year attributable to equity shareholders by weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share net profit or loss for the year attributable to equity shareholders and weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

F. Provisions and Contingent Liabilities

Provisions: Provisions are recognized when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date and are not discounted to its present value.



Y. Sambasivam

S. Malathi

NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2019-20
NOTES forming part of the Financial Statements

G. Cash and Cash Equivalents:

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash and Cash equivalents for the purpose of cash flow statement comprise cash at bank and in hand and short term investments with an original maturity of not more than three months.

Disclosures Required by Accounting Standards:

H. Other Disclosures:

(i) Earnings Per Share :

Particulars	As at 31.03.2020	As at 31.03.2019
a. Net Profits Attributable to Equity Shareholders	4710	(7000)
b. Weighted Average No of Equity Shares Outstanding during the Year	10,000	10,000
c. Add: Dilutive effect of potential ordinary Shares outstanding	NIL	NIL
d. Weighted average number of Ordinary shares in computing diluted earnings per share	10,000	10,000
Earnings per Share for the face value of Rs.10		
- Basic (a/b)	0.47	(0.70)
- Dilutive(a/d)	0.47	(0.70)

(ii) Related Party Disclosure:

Related parties:

Name of the Related Party	Nature of Relationship
Sambasiva Rao Yeluri	Director
MalathiSiripurapu	Director



Y. Sambasiva Rao *S. Malathi*

NOVA HEALTH SCIENCES PRIVATE LIMITED: Financial Year 2019-20
NOTES forming part of the Financial Statements

Directors/KMP:

Particulars	31.03.2020	31.03.2019
Salary/Remuneration	-	-
Advances given by Company		
Opening Balance	-	-
Transactions during the year	-	-
Closing Balance	-	-
Advances taken by Company		
Opening Balance	-	-
Transactions during the year	-	-
Closing Balance	-	-

(iii) Remuneration to Statutory Auditor:

Particulars	For the year ended	For the year ended
	March 31,	March 31,
	2020	2019
Audit Fees	7,000	7,000
Total	7,000	7,000


For NSVR & ASSOCIATES LLP.
Chartered Accountants
FRNo.008801S/S200060




P. VenkataRatnam
Partner
Membership No.230675
UDIN: 21230675AAAADJ2620

Place: Hyderabad
Date : 28-9-2020

On & behalf of Board of directors
Nova Health Sciences Private Limited



SambaSiva Rao Yeluri
Director
(DIN:02311336)



MalathiSripurapu
Director
(DIN:03033944)



INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF NOVA HEALTH SCIENCES PRIVATE LIMITED

Report on the Audit of the Financial Statements Opinion:

We have audited the accompanying financial statements of **Nova Health Sciences Private Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2020, and the Statement of Profit and Loss for the year ended on that date, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, the profit for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be communicated in our audit report.


Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards referred to in Section 133 of Companies Act 2013. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.


Auditor's Responsibilities for the Audit of the Financial Statements

Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the Accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



The block contains a handwritten signature in blue ink, which appears to be 'P. V. S.', written over a circular official stamp. The stamp is partially obscured by the signature and contains some illegible text and a central emblem.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication



The block contains a handwritten signature in blue ink and a circular stamp. The stamp is purple and contains the text 'NSVR & ASSOCIATES LLP.' around the perimeter and 'CHARTERED ACCOUNTANTS' in the center.

1. As required by the Companies (Auditor's Report) Order, 2016, issued by the department of company affairs, in terms of section 143 (11) of the companies Act, 2013, and on the basis of our examination of the books and records as we considered appropriate and according to the information and explanation given to us.

2. As required by section 143(3) of the Companies Act 2013, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.

b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.

c) The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid financials comply with the Accounting Standards specified under of Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of written representations received from the directors as on March 31, 2020, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2020, from being appointed as a director in terms of sub section (2) of section 164 of the Companies Act, 2013.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively throughout the period of audit


g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i) There are no pending litigations for or against the Company which would impact its financial position.

ii) The Company does not have any derivatives contracts. Further there are no long term contracts for which provisions for any material foreseeable losses is required to be made.

iii) There are no amounts pending that are required to be transferred to Investor Education and Protection Fund.

For NSVR & ASSOCIATES LLP.,
Chartered Accountants
(FRN No.008801S/S200060).


P Venkata Ratnam
Partner
M.no:230675.
UDIN: 21230675AAAADJ2620

Date: 28-9-2020
Place: Hyderabad.

NOVA HEALTH SCIENCES PRIVATE LIMITED


CIN: U8S190TG2010PTC068S84

R.O.: S.Y.No:2,5L/1,SINGANNAGUDA VILLAGE, MULUGU MANDAL, SIDDIPET DISTRICT -502279

List of Shareholders and their shareholding as on 31-03-2020

S. No.	Name and Address of the Shareholder	Type of Shares	Number of Shares	Amount per Share (in Rs.)
1	Mr. Sambasivarao Yeluri	Equity	8,000	10
2	Mrs. Malathi Siripurapu	Equity	2,000	10
Total			10,000	

For, NOVA HEALTH SCIENCES PRIVATE LIMITED



Sambasivarao Yeluri

Director

DIN: 02311336